Skip to main content

Table 4 Inhibitory activity of hexavalent Nucant pseudopeptides N6, N7, and N6L in tumor cell lines of different origins.

From: Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type

Cell line

Tumor cell origin

% Growth inhibition

% Cell death

  

After 3 days

(N6/N7 - N6L)

After 24 hours

(N6/N7 - N6L)

MDA-MB 231

Hu breast cancer

92 - 95%

< 5%

MDA-MB 435

Hu breast cancer

58 - 66%

< 5%

LNCaP

Hu prostate cancer

88 - 90%

< 5%

HeLa

Hu cervical cancer

46 - 60%

< 5%

SW480

Hu colon carcinoma

25 - 35%

< 5%

SW620

Hu colon carcinoma

45 - 55%

< 5%

TIII

Mu melanoma cells

55 - 83%

< 5%

HuT 78

Hu cutaneous T cell leukemia

62 - 83%

44 - 55%

Jurkat

Hu T-cell leukemia

80 - 85%

45 - 60%

RAJI

Hu Burkitt lymphoma

75 - 95%

42 - 71%

HL60

Hu acute promyelocytic leukemia

65 - 80%

35 - 48%

T29

Mu T-cell lymphoma

85 - 95%

45 - 65%

  1. Epithelial (MDA-MB 231, MDA-MB 435, LNCaP, HeLa, SW480, SW620, TIII) and leukemia (HuT 78, Jurkat, RAJI, HL60, and T29) cell lines were cultured in the absence or presence of N6 or N7 (20 μM) or N6L (10 μM) to test their inhibitory activity on cell growth (by measuring viable cell number after 3 days of culture) and cell death (by monitoring the trypan blue uptake after 24 hours of treatment of subconfluent epithelial and freshly passaged leukemia cells). The number of viable cells in untreated control samples was used to calculate the % inhibition of cell growth and % cell death. Hu and Mu stand for human and murine origin, respectively. The mean percentage values of at least 2 independent experiments are presented.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us